On Oct. 16, 2017, Ablynx, a Belgian biopharmaceutical company focused on the discovery and development of nanobodies, announced the establishment of its US-based subsidiary, Ablynx, Inc., and the appointment of Daniel Schneider as general manager to lead the commercialization of caplacizumab inOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.